Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans

Platelets

Volumn 21, Issue 6, 2010, Pages 464-469

  Spiel, Alexander O ^a   Siller Matula, Jolanta ^a   Firbas, Christa ^a   Leitner, Judith M ^a   Russmueller, Guenter ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

G CSF; platelets; thrombelastography; tissue factor; vWF:RiCO

Indexed keywords

ADRENALIN; COLLAGEN; MESSENGER RNA; PROTHROMBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISTOCETIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ADULT; BLOOD DONORS; BLOOD PLATELETS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; PLATELET AGGREGATION; PLATELET COUNT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 77955897278     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.485255     Document Type: Article

References (32)

1. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992;327:28-35.
2. Majolino I, Cavallaro AM, Scime R. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant 1996;18(Suppl 2):171-174.
3. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-311.
4. Kastrup J, Ripa RS, Wang Y, Jorgensen E. Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy? Eur Heart J 2006;27:2748-2754.
5. Zhou B, Bi YY, Han ZB, et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost 2006;4:993-1002.
6. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007;98:1335-1342.
7. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999;93:2506-2514.
8. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999;23:991-996.
9. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 2004;33:171-176.
10. Avenarius HJ, Freund M, Deinhardt J, Poliwoda H. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets. Ann Hematol 1992;65:6-9.
11. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993;91:1310-1313.
12. Spiel AO, Mayr FB, Ladani N, et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009;20:334-340.
13. Gouya G, Jilma B, Niel M, Eichelberger B, Wolzt M, Panzer S. Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial. Platelets 2009;20:171-176.
14. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-2552.
15. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006;48:2178-2185.
16. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008;19:104-110.
17. Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006;4:411-416.
18. Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 2004;32:1136-1140.
19. Feuring M, Wehling M, Ruf A, Schultz A. Circadian variation of platelet function measured with the PFA-100. Platelets 2009;20:466-470.
20. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003;102:4594-4599.
21. Jilma B, Blann A, Pernerstorfer T, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999;159:857-863.
22. Reiter R, Derhaschnig U, Spiel A, et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003;90:898-903.
23. Kaptan K, Ifran A, Beyan C, Sertkaya D. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) promotes in vitro platelet aggregation. Hematology 2007;12:441-444.
24. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008;117:1449-1459.
25. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-1397.
26. Spiel AO, Frossard M, Mayr FB, et al. Pronounced platelet hyperfunction in patients with cardiac arrest achieving restoration of spontaneous circulation. Crit Care Med 2009;37:975-979.
27. Stephens DP, Thomas JH, Higgins A, et al. Randomized, double-blind, placebo-controlled trial of granulocyte colonystimulating factor in patients with septic shock. Crit Care Med 2008;36:448-454.
28. Fukumoto Y, Miyamoto T, Okamura T, et al. Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acute myelogenous leukaemia. Br J Haematol 1997;97:666-668.
29. Vij R, Adkins DR, Brown RA, Khoury H, DiPersio JF, Goodnough T. Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor. Transfusion 1999;39:542-543.
30. Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1643-1648.
31. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. JAMA 2006;295:1003-1010.
32. Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009;102:397-403.